13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000310158
Total reported value
$526.4M
$526.4M
14 檔
59.0%
At the close of Q1 2026, Merck & Co., Inc. disclosed equity holdings valued at approximately $526.4M, spread across 14 reported holdings.
In Q1 2026, Merck & Co., Inc. displayed an active expansion posture, initiating 3 new positions and adding to 1 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including MRNA, PSNL, KYMR) accounted for 59.0% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MRNA | Moderna Inc | Stock-Healthcare | 33.56% | -2.85% | — | |
| 2 | PSNL | Personalis Inc | Stock-Other | 25.60% | +10.15% | — | |
| 3 | KYMR | Kymera Therapeutics Inc | Stock-Other | 18.40% | -1.58% | — | |
| 4 | ✓ | Stock-Other | 6.28% | -6.28% | EXIT | ||
| 5 | EIKN | Eikon Therapeutics Inc | Stock-Other | 5.05% | -0.92% | — | |
| 6 | AKTS | Aktis Oncology Inc | Stock-Other | 4.88% | +0.95% | — | |
| 7 | ALEC | Alector Inc | Stock-Other | 2.18% | -0.83% | — | |
| 8 | STRO | Sutro Biopharma, Inc. | Stock-Other | 1.94% | -1.94% | EXIT | |
| 9 | EVAXUSD | Evaxion Biotech A/s | Stock-Other | 1.29% | -1.29% | EXIT | |
| 10 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.52% | -0.19% | — | |
| 11 | XLO | Xilio Therapeutics Inc | Stock-Other | 0.26% | -0.07% | — | |
| 12 | CARM | Carisma Therapeutics Inc | Stock-Other | 0.01% | -0.01% | EXIT | |
| 13 | NEUP | Neuphoria Therapeutics Inc | Stock-Other | 0.01% | — | — | |
| 14 | HURA | Tuhura Biosciences Inc | Stock-Other | 0.01% | — | +39.39% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MRNA | Moderna Inc | +8.9% | — | Unchanged |
| 2 | STRO | Sutro Biopharma, Inc. | +0.8% | — | Unchanged |
| 3 | ALEC | Alector Inc | +0.2% | — | Unchanged |
| 4 | HURA | Tuhura Biosciences Inc | 0% | +39.39% | Add |
| 5 | NEUP | Neuphoria Therapeutics Inc | — | — | Unchanged |
| 6 | CARM | Carisma Therapeutics Inc | 0% | — | Unchanged |
| 7 | ✓ | -0.2% | — | Unchanged | |
| 8 | VRDN | Viridian Therapeutics Inc | -0.5% | — | Unchanged |
| 9 | EVAXUSD | Evaxion Biotech A/s | -0.8% | — | Unchanged |
| 10 | KYMR | Kymera Therapeutics Inc | -3.4% | — | Unchanged |
| 11 | PSNL | Personalis Inc | -14.9% | — | Unchanged |
| 12 | EIKN | Eikon Therapeutics Inc | — | NEW | New buy |
| 13 | AKTS | Aktis Oncology Inc | — | NEW | New buy |
| 14 | ✓ | Xilio Therapeutics Inc | — | EXIT | Sold out |
| 15 | XLO | Xilio Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Merck & Co., Inc. reported a total U.S. public equity portfolio value of $526.4M across 14 disclosed positions in Q1 2026.
During Q1 2026, Merck & Co., Inc.'s top holdings by market value included MRNA (33.6%)、PSNL (25.6%)、KYMR (18.4%). The largest single position, MRNA, represented 33.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
EIKN
市值: $17.6M
Top Position Liquidated / Trimmed
XILIO THERAPEUTICS INC
前期市值: $949.9K
In Q1 2026, Merck & Co., Inc. made 5 total portfolio adjustments, initiating 3 new buys, adding to 1 positions, trimming 0 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.